Business ❯ Healthcare

Pharmaceuticals

Drug Development Clinical Trials Weight Loss Drugs Market Competition Drug Pricing Acquisitions Biotechnology Manufacturing Vaccine Development Oncology

MoonLake Investors Press Securities Class Action Over Sonelokimab Claims

Investors have until December 15, 2025 to seek lead-plaintiff status in the newly filed case.

Judge Lets Novo’s $10 Billion Metsera Bid Proceed as FTC Flags Antitrust Risks

Cramer Calls Pfizer ‘Uninvestible’ After Q3 Beat, Citing No Growth Engine and Seagen Letdown

Savara Investors Pressed to Meet Class-Action Deadlines Over Alleged MOLBREEVI BLA Deficiencies

New aTyr Class Action Expands Investor Window After EFZO-FIT Failure

AstraZeneca Beats Q3 Expectations, Reaffirms 2025 Guidance

Moderna Trims 2025 Forecast as Q3 Loss Narrows and Revenue Beats

Cytokinetics Investors Face Nov. 17 Deadline to Seek Lead Role in Aficamten Securities Case

AstraZeneca Posts Record Quarter as Cancer Drugs Lift Sales, Keeps Guidance

Cencora Commits Over $1 Billion to U.S. Drug Distribution Buildout Through 2030

Novo Nordisk Raises Metsera Bid to $10 Billion, Outpacing Pfizer’s $8.1 Billion Counter

MoonLake Investors Face Dec. 15 Lead-Plaintiff Deadline as Securities Case Advances in SDNY

Amgen Raises Outlook on Q3 Beat as MariTide Milestones Approach

Savara Securities Case Nears Lead‑Plaintiff Deadline as Firms Court Investors

Pfizer Tops Q3 Forecasts, Raises Profit Outlook

Eli Lilly Unveils $3 Billion Netherlands Plant to Scale Production of Oral Weight‑Loss Pill

Eli Lilly Unveils $3 Billion Netherlands Plant for Oral GLP-1 Medicines as Stock Rises

FDA Setback Puts uniQure’s Huntington’s Gene Therapy Filing in Doubt

Pfizer Sues Metsera and Novo Nordisk to Block Termination of $4.9 Billion Deal

Eli Lilly Lifts 2025 Guidance After Tirzepatide Fuels Blowout Quarter